CAP-1(6D) and CMVpp65 peptide-pulsed autologous dendritic cell vaccine

This is a dendritic cell-based cancer vaccine developed by Duke University for the treatment of stage IV CEA-expressing malignancies, including colorectal, pancreatic, lung, and breast cancers. The vaccine utilizes autologous dendritic cells derived from the patient, which are pulsed with two specific peptide antigens: CAP-1(6D) and CMV pp65. CAP-1(6D) is an altered peptide ligand derived from carcinoembryonic antigen (CEA), where asparagine at position 6 is replaced by aspartic acid (sequence: YLSGADLNL) to enhance T-cell activation and bypass immune tolerance. CMV pp65 is included to provide additional T-cell help and potent immune stimulation. The vaccine aims to induce a robust cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CEA, which is found in over 90% of certain gastrointestinal and respiratory cancers.

Other names

CEA peptide 1-6DCAP-1(6D) and CMVpp65 Dendritic Cell VaccineCAP-1(6D) peptide-pulsed, matured, autologous human DC